Guardian Partners’s AbbVie ABBV Stock Holding History

Guardian Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$449K	Sell	1,785 -192	-10%	-$41.3K	0.04%	155
2026 Q1	$430K	Buy	1,977 +1	+0.1%	+$222	0.04%	150
2025 Q4	$429K	Buy	+1,976	New	+$450K	0.03%	162

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Guardian Partners's ABBV Position: Q2 2026 in Review

Guardian Partners reduced its AbbVie (ABBV) stake by 9.7% in Q2 2026, selling an estimated $41.3K and leaving 1,785 shares worth $449K. The position accounts for 0.04% of the portfolio, ranked #155.

Guardian Partners first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,220 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Guardian Partners held 1,785 shares of AbbVie worth $449K as of Q2 2026.
Guardian Partners sold 192 AbbVie shares in Q2 2026, an estimated $41.3K.
AbbVie made up 0.04% of Guardian Partners's portfolio in Q2 2026, its #155 holding.
Guardian Partners first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,220 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Guardian Partners's 13F filing for Q2 2026, filed 29 Jul 2026.